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Article Information  ABSTRACT 
Received: 29th January 2020  A novel, simple, precise and accurate method developed for the estimation of Lamivudine and tenofovir 
disoproxil fumarate (TDF) in bulk drug form has been established. Lamivudine and tenofovir are well 
known drugs and used in treatment of HIV- Ⅰ. The method was performed by using   C18 column, 
ODS Hypersil column with UV detection at 262nm by using Acetonitrile and water in ratio 55:45. The 
retention time was found to be 2.8 and 6.8 min for Lamivudine and tenofovir disoproxil fumarate 
(TDF). The linearity was found in range of 6- 14µg/ml for Lamivudine and 10- 50µg/ml for Tenofovir 
disoproxil fumarate with flow rate 1ml/min. the method was validated for linearity, accuracy, precision 
and robustness as per ICH guidelines. This method is suitable for simultaneous analysis for both the 
nucleoside analog reverse- transcriptase inhibitors 
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INTRODUCTION 
 Tenofovir disoproxil fumarate (Fig-1) and Lamivudine (Fig-2) 
are widely used anti-retroviral drugs in the categories of NRTIs 
i.e. nucleotide analogues reverse transcriptase inhibitors [1-4]. 
These drugs are used for the prevention and clinical management 
of acquired immune deficiency syndrome (AIDS) with multiple 
complications [5-8].  
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Lamivudine is commonly called 3TC used in the treatment of 
HIV/AIDS and also treat chronic hepatitis B where the virus that 
causes complicated liver inflammation. It slow down and 
prevent damage to immune system and reduce the risk of 
developing AIDS related illnesses. Lamivudine help fight the 
virus and slow the ability to damage liver [9-12]. 
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Tenofovir is type of anti-HIV medicine called a nucleoside 
reverse transcriptase inhibitor (NRTI). It is always used in 
combination with other antiviral agents to treat patients with 
HIV. It is used in the form of pro- drug as Tenofovir Disoproxil 
Fumarate [13-15]. Tenofovir is not cure for HIV infection but 
decrease risk of spreading HIV disease to others. It also used to 
treat the certain type of liver infection called chronic hepatitis B 
infection [16-18]. The literature review revealed that there are 
several methods available for single component analysis for 
lamivudine and Tenofovir (TDF) [19-20].  
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Figure 1: Tenofovir (TDF) 
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Figure 2: Lamivudine 
 
MATERIAL AND METHOD 
Instrument  
The lambda max and iso-absorptive point were determined by 
UV –spectrophotometer using Lab India with UV win software. 
HPLC (Shimadzu) prominence LC 20 AD,  manual sampler, 
software LC solution  and detector (UV-visible), Column C-18, 
Thermo scientific octadecylsilane  Hypersil (ODS), ultra-
sonicater, vacuum filter, analytical balance. 
 
Selection of wavelength 
The selection of wavelength 10 µg/ml concentration of 
lamivudine and 10µg/ml concentration of tenofovir was 
prepared in 55:45 with ACN: water respectively. The result 
show iso-absorptive point that was observed at 262 nm (figure 
3). 
 
Figure 3. Overlain spectrum of lamivudine and TDF 
 
Selection of chromatographic condition  
The isocratic mode with mobile phase Acetonitrile and water in 
ratio 55:45 with flow rate 1ml/min. The resulting 
chromatograms were recorded and the chromatographic 
responses were measured. 
 
Analytical Method Validation 
A calibration curve was plotted with the concentration range 6-
14µg/ml for lamivudine and 10-50µg/ml for tenofovir (TDF). 
The method was developed and validated as per ICH guidelines. 
The parameters were studied linearity, accuracy, precision 
(intraday and interday precision and repeatability) and 
robustness and the amount recovery, percentage recovery and 
mean recovery for the same was calculated. 
 
Preparation of standard stock solution  
Lamivudine standard stock solution 
Standard lamivudine 100 mg was weighed and transferred to a 
100 ml clean and dry volumetric flask and dissolved into the 
HPLC grade sample solution (ACN: Water in the ratio 55:45) 
then volume was made up to the mark with  solution containing 
1000µg/ml conc. Then 10 ml of solution was pipette out and 
transferred to 100 ml clean and dry volumetric flask, made up its 
volume with solvent to get 100 µg/ml conc. solutions. 
 
TDF standard stock solution  
Standard tenofovir (TDF) 100 mg was weighed and transferred 
to a 100 ml clean and dry volumetric flask and dissolved into the 
HPLC grade sample solution (ACN: Water in the ratio 55:45) 
then volume was made up to the mark with solution containing 
1000 µg/ml conc. Then 10 ml of solution was pipette out and 
transferred to 100 ml clean and dry volumetric flask, made up its 
volume with solvent to get 100 µg/ml conc. solutions. 
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Chromatographic conditions 
The mobile phase consisting of Acetonitrile: water (55:45) was 
used and absorbance was measured at 262 with the run time 15 
min and the flow rate was set at 1.0 ml/min respectively. 
Preparation of mobile phase  
Mobile phase was prepared by mixing HPLC grade acetonitrile 
and water in ratio of 55: 45 respectively, and the 
chromatographic conditions were made for separation of the 
drugs at the wavelength of 262nm. Degassing is done before the 
use of mobile phase. 
 
Figure 4: Chromatogram of lamivudine at wavelength 
262nm 
 
Figure 5: Chromatogram of tenofovir (TDF) at wavelength 
262nm 
 
Figure 6: Chromatogram of both drugs at 262nm 
 
Validation of the developed method 
Linearity curve for lamivudine 
Standard lamivudine stock solution the volume of 0.6, 0.8, 1, 
1.2, 1.4ml was pipetted out from 100µg/ml and transferred to 
different 10 ml clean and dry volumetric flasks. The volume was 
made up to the mark having conc. of 6, 8, 10, 12, 14µg/ml 
respectively. The injection was prepared 20µg/ml and given with 
run time of 15 minutes. The linearity peaks was found to be 
within the limits. The results are shown in figure 7 and table 1. 
Table: 1. Results of linearity curve of Lamivudine at 
wavelength 262 nm. 
S. No  Conc. (µg/mL)  Area (µ volt sec.)  
1  6 376003 
2  8 651314 
3  10 866679 
4  12 1108256 
5  14 1357247 
 
Figure 7: Linearity curve of lamivudine at 262nm 
 
Linearity curve for tenofovir (TDF) 
Standard tenofovir (TDF) stock solution the volume of 1, 2, 3, 
4, 5, 6 ml was pipetted out from 100µg/ml and transferred to 
different 10ml clean and dry volumetric flasks. Then volume 
was made up to the mark having conc. of 10, 20, 30, 40, 50, 
60µg/ml respectively. The injection was given 20µg/ml with run 
time of 15 minutes. The linearity peaks was found to be within 
the limits. The results are shown in figure 8 and table 2. 
 
Accuracy  
To study the accuracy, 3 determinants of conc. range of 8, 10, 
12µg/ml for lamivudine and 20, 30, 40 µg/ml for tenofovir 
(TDF0 were prepared having 80%, 100%, and 120% of spiked 
level respectively. 3 replicates of above conc. were prepared and 
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responses were obtained. Percent recovery was calculated for 
obtained data and calculated according to ICH guidelines (Table 
3 and 4). 
 
Table 2. Result of linearity curve of tenofovir (TDF) at 
262nm 
S. No Conc. (µg/mL) Area (µ volt sec.) 
1 10 427228 
2 20 733996 
3 30 1101386 
4 40 1481526 
5 50 1916508  
Figure 8. Linearity curve of tenofovir (TDF) at 262nm 
Drug recovery  
80%   = (Mean of abs.  of 180% fortified sample−mean abs.of 80% unfortified sample)Mean abs.of fortified standard solution of 100% test conc. × 100 
100% =  (Mean abs.of 200% fortified sample−Mean abs.of 100 unfortified sample)
Mean abs.of fortified standard solution of 100% test conc.
× 100 
120% = (Mean abs.of 220% fortified sample−Mean abs.of 120% unfortified sample)
Mean abs.of fortified standard solution of 120% test conc.
× 100 
 
Table 3: % Drug Recovery of lamivudine at wavelength 262nm 
S. 
No. 
Unfortified sample Fortified sample % Recovery 
Conc. (μg/ml) Area Mean Conc. (μg/ml) Area Mean 
1 8   651315 
  651313 
  651314 
  651314 8+10  1517973 
 1517971 
 1517970 
 1517971 99.34 
2 10   866680 
  866678 
  866679 
  866679 10+10  1733398 
 1733400 
 1733396  
 1733398 100.02 
3 12   1108257 
  1108255 
  1108254 
 
1108257 
12+10  1974929 
 1974927 
 1974927 
 1974927 99.05 
 
Table 4: % Drug recovery of tenofovir (TDF) at wavelength 262nm 
S. 
No. 
Unfortified sample Fortified sample % 
Recovery Conc. (μg/ml) Area Mean Conc. (μg/ml) Area Mean 
1 20   733996 
  733976 
  733996 
  733989 20+30  1835268 
 1835270 
 1835269 
 1835269 99.06 
2 30   1101386 
  1101389 
  1101387 
  1101388 30+30  2202799 
 2202797 
 2202799 
 2202798 100.0 
3 40  1481526 
 1481429 
 1481428 
 1481461 40+30  2582813 
 2582811 
 2582812 
 2582812 99.76 
y = 37261x + 14302
R² = 0.9962
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Precision  
The precision was done for interday, intraday and repeatability.  
Interday & intraday precision   
Interday & intraday precision of conc. 8, 10, 12µg/ml was 
prepared and data was obtained for lamivudine.  
Interday & intraday precision of conc. 20, 30, 40µg/ml was 
prepared and data was obtained for tenofovir (TDF). 3 replicates 
were prepared for 3 days.  
The results of lamivudine and tenofovir were shown in table 5 to 
7. 
 
Table 5: Intraday precision of lamivudine and tenofovir(TDF) at 262nm 
Drug  Lamivudine  Tenofovir (TDF) 
Conc.  8 µg/ml 10 µg/ml 12 µg/ml 20µg/ml 30µg/ml 40µg/ml 
Area  
(µ volt sec.) 
651314 866679 1108256 733996 1101386 1481526 
651294 866580 1108350 733954 1101285 1481429 
651229 866662 1108275 733889 1101324 1481494 
Mean  651279 866640.3 1108294 733946.3 1101332 1481483 
S D  44.440 52.937 49.702 53.910 50.934 49.426 
% RSD  0.0068 0.0061 0.0044 0.007 0.004 0.003 
 
Table 6: Interday precision of lamivudine at 262nm 
Day  Day 1 Day 2 Day3 
Conc.  8µg/ml 10µg/ml 12µg/ml 8µg/ml 10µg/ml 12µg/ml 8µg/ml 10µg/ml 12µg/ml 
Area  
(µ volt 
sec.) 
651314 866679 1108256 651379 866679 1108256 651314 866679 1108256 
651294 866580 1108350 651314 866558 1108344 651226 866685 1108375 
651229 866662 1108275 651215 866679 1108298 651289 866589 1108226 
Mean  651279   866640.3 1108294 651302.7 866638.7 1108299 651276.3 866651 1108286 
S D  44.440 52.937 49.702 82.585 69.859 44.015 45.346 53.777 78.805 
%RSD  0.0068 0.0061 0.0044 0.012 0.008 0.003 0.0069 0.0062 0.0071 
 
Table 7:  Interday precision of tenofovir (TDF) at 262nm 
Day  Day 1 Day 2 Day 3 
Conc.  20µg/ml 30µg/ml 40µg/ml 20µg/ml 30µg/ml 40µg/ml 20µg/ml 30µg/ml 40µg/ml 
Area  
(µ volt 
sec.) 
733996 1101386 1481526 733987 1101287 1481437 733996 1101386 1481432 
733954 733954 1481429 733996 1101386 1481525 733887 1101476 1481526 
733889 733889 1481494 733999 1101296 1481516 733992 1101394 1481489 
Mean  733946.3 733946.3 1481483 733994 1101323 1481493 733958.3 1101419 1481482 
S D  53.910 53.910 49.426 6.244 54.744 48.418 61.80885 49.81298 47.35328 
%RSD  0.007 0.007 0.003 0.0008 0.0049 0.0032 0.0084 0.0045 0.0031 
 
Repeatability  
For repeatability determination minimum of 6 determinants 
were prepared of 20µg/ml conc. and the chromatogram 
responses were obtained. The results of lamivudine and 
tenofovir (TDF) were shown in table 8 
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Table 8: Repeatability of lamivudine and TDF at 262nm 
S. No Area (µ volt sec.) Area (µ volt sec.) 
1 866699 1101386 
2 866624 1101285 
3 866612 1101324 
4 866682 1101386 
5 866645 1101476 
6 866657 1101394 
Mean 866645 1101332 
S D 47.148 50.934 
%RSD 0.005 0.0046 
 
Robustness  
This method was carried out by changing wavelength and flow 
rate of mobile phase. The results were shown in table 9 for 
change in mobile phase and table 10 for change in flow rate. 
Table: 9 Robustness of lamivudine & tenofovir (TDF) at 
wavelength 262±2nm. 
Wavelength Difference Rt of Lamivudine 
(min.) 
Rt of Tenofovir 
(min.) 
260 -2 2.769 6.883 
262 0 2.858 6.881 
264 +2 2.841 6.888 
  
Change in flow rate of mobile phase   
Table: 10 Robustness of lamivudine & tenofovir (TDF) at 
wavelength 262 nm.  
Flow rate 
(mL/min.) 
Difference Rt of Lamivudine 
(min.) 
Rt of Tenofovir 
(min.) 
0.9 -0.1 2.752 6.780 
1 0 2.858 6.880 
1.1 +0.1 2.285 6.898 
 
CONCLUSION  
The estimation of lamivudine and Tenofovir (TDF) was done by 
RP-HPLC. The mobile phase was optized Acetonitrile: water in 
the ratio of 55:45% v/v. A C18 column contains octa-decylsilane 
chemically linked to porous silica particles was used as 
stationary phase. UV detector was used at 262 nm. The solutions 
were chromatograph at a constant flow rate of 1 ml/min. The 
linearity range of lamivudine was found 6- 14µg/ml and 
tenofovir (TDF) were found to be 10-50µg/ml. Linear regression 
coefficient was not more than 0.999. 
The results obtained on the validation parameters met ICH and 
USP requirements. It can be also inferred that the method found 
to be simple, accurate, precise and linear. The method was found 
to be having suitable application in routine laboratory analysis 
with high degree of accuracy and precision. 
Table 11: Summary of developed method 
Parameter  
 
Lamivudine Tenofovir  
Linearity range (µg/ml) 6-14 10- 50 
Regression coefficient (R2) 0.999 0.999 
% Recovery 99.47 99.60 
Repeatability (n=6) % RSD NMT 2 % RSD NMT 2 
Precision  
Intraday precision 
Interday precision 
 
% RSD NMT 2 
 
% RSD NMT 2 
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